4//SEC Filing
Syndax Pharmaceuticals Inc 4
Accession 0000904454-16-001107
$SNDXCIK 0001395937operating
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 11:41 AM ET
Size
18.0 KB
Accession
0000904454-16-001107
Insider Transaction Report
Form 4
DOVEY BRIAN H
10% Owner
Transactions
- Conversion
Series B-1 Preferred Stock
2016-03-08−2,967→ 0 total→ Common Stock (2,967 underlying) - Conversion
Series C-1 Preferred Stock
2016-03-08−2,674→ 0 total→ Common Stock (2,674 underlying) - Conversion
Common Stock
2016-03-08+5,641→ 5,641 total
DP VIII Associates, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2016-03-08+5,641→ 5,641 total - Conversion
Series B-1 Preferred Stock
2016-03-08−2,967→ 0 total→ Common Stock (2,967 underlying) - Conversion
Series C-1 Preferred Stock
2016-03-08−2,674→ 0 total→ Common Stock (2,674 underlying)
BLAIR JAMES C
10% Owner
Transactions
- Conversion
Common Stock
2016-03-08+5,641→ 5,641 total - Conversion
Series B-1 Preferred Stock
2016-03-08−2,967→ 0 total→ Common Stock (2,967 underlying) - Conversion
Series C-1 Preferred Stock
2016-03-08−2,674→ 0 total→ Common Stock (2,674 underlying)
VITULLO NICOLE
10% Owner
Transactions
- Conversion
Common Stock
2016-03-08+5,641→ 5,641 total - Conversion
Series C-1 Preferred Stock
2016-03-08−2,674→ 0 total→ Common Stock (2,674 underlying) - Conversion
Series B-1 Preferred Stock
2016-03-08−2,967→ 0 total→ Common Stock (2,967 underlying)
Halak Brian K
10% Owner
Transactions
- Conversion
Series C-1 Preferred Stock
2016-03-08−2,674→ 0 total→ Common Stock (2,674 underlying) - Conversion
Common Stock
2016-03-08+5,641→ 5,641 total - Conversion
Series B-1 Preferred Stock
2016-03-08−2,967→ 0 total→ Common Stock (2,967 underlying)
TREU JESSE I
10% Owner
Transactions
- Conversion
Common Stock
2016-03-08+5,641→ 5,641 total - Conversion
Series B-1 Preferred Stock
2016-03-08−2,967→ 0 total→ Common Stock (2,967 underlying) - Conversion
Series C-1 Preferred Stock
2016-03-08−2,674→ 0 total→ Common Stock (2,674 underlying)
Footnotes (6)
- [F1]All outstanding Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.
- [F2]The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F3]As managing members of the sole general partner of Domain Partners VIII, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own the securities of the Issuer held by Domain Partners VIII, L.P, as reported on a Form 4 for Domain Partners VIII, L.P., filed on the same date as this Form 4.
- [F4]As managing members of the sole general partner of Domain Partners VI, L.P., each Reporting Owner listed below (except for Brian K. Halak) may also be deemed to indirectly beneficially own the securities of the Issuer held by Domain Partners VI, L.P., as reported on a Form 4 for Domain Partners VI, L.P. filed on the same date as this Form 4.
- [F5]As managing members of the sole general partner of DP VI Associates, L.P., each Reporting Owner listed below (except for Brian K. Halak) may also be deemed to indirectly beneficially own the securities of the Issuer held by DP VI Associates, L.P., as reported on a Form 4 for DP VI Associates, L.P. filed on the same date as this Form 4.
- [F6]As managing members of Domain Associates, LLC, each Reporting Owner listed below may also be deemed to indirectly beneficially own 13,564 shares of Common Stock held by Domain Associates, LLC.
Documents
Issuer
Syndax Pharmaceuticals Inc
CIK 0001395937
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001395937
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 11:41 AM ET
- Size
- 18.0 KB